Immunome (IMNM) Expected to Announce Quarterly Earnings on Thursday

Immunome (NASDAQ:IMNM) is projected to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.6037) per share and revenue of $0.15 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.14). On average, analysts expect Immunome to post ($2.48) EPS for the current fiscal year and ($2.76) EPS for the next fiscal year.

Immunome Stock Performance

Shares of NASDAQ IMNM opened at $19.59 on Tuesday. Immunome has a 52-week low of $14.64 and a 52-week high of $30.06. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of -7.74 and a beta of 2.55. The stock has a 50 day moving average price of $22.26 and a 200 day moving average price of $22.46.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. William Blair started coverage on Immunome in a research report on Friday, October 16th. They set an “outperform” rating for the company. Stifel Nicolaus started coverage on Immunome in a research report on Wednesday, September 30th. They set a “hold” rating and a $24.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research report on Thursday, October 15th. HC Wainwright restated a “buy” rating on shares of Immunome in a research note on Tuesday, October 27th. Finally, Alliance Global Partners began coverage on Immunome in a report on Monday, September 21st. They issued a “buy” rating and a $32.00 price objective for the company. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.25.

Insider Buying and Selling

In related news, insider Jack Higgins sold 13,200 shares of Immunome stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $25.32, for a total transaction of $334,224.00. Following the transaction, the insider directly owned 65,050 shares of the company’s stock, valued at $1,647,066. This trade represents a 16.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 62,291 shares of Immunome stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $26.23, for a total transaction of $1,633,892.93. Following the transaction, the director directly owned 92,211 shares in the company, valued at approximately $2,418,694.53. The trade was a 40.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 132,752 shares of company stock worth $3,473,587. Insiders own 7.21% of the company’s stock.

About Immunome

Immunome, Inc (NASDAQ: IMNM) is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines. Its technology platform analyzes human immune responses to identify antibodies that may be developed into therapies for serious diseases.

The company’s research activities have included therapeutic programs in oncology and immunology, with an emphasis on antibodies designed to affect disease-driving biological pathways. Immunome has also conducted antibody discovery work related to infectious diseases, including SARS-CoV-2, as it has expanded its focus toward broader therapeutic applications.

Immunome is headquartered in Exton, Pennsylvania, and serves the global biopharmaceutical market through internal research and development activities and potential collaborations.